A Double-Blind, Controlled Phase 2 Study of the Safety and Efficacy of Modified Stem Cells (SB623) in Patients With Chronic Motor Deficit From Traumatic Brain Injury (TBI)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 09 Apr 2018
At a glance
- Drugs SB 623 (Primary)
- Indications Brain injuries
- Focus Therapeutic Use
- Acronyms STEMTRA
- Sponsors SanBio
- 01 Apr 2018 According to a SanBio media release, the company plans to publish clinical trial results form this TBI study by the end of the fiscal year ending January 2019 and file for approval in the fiscal year ending January 2020.
- 01 Apr 2018 Status changed from recruiting to active, no longer recruiting, according to a SanBio media release.
- 13 Mar 2018 According to a SanBio media release, enrollment for this trial is close to complete.